TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32182353

Group type: EXPERIMENTAL
Intervention: Daily cash incentives
Number of subjects: 274

Group type: COMPARATOR
Intervention: Action planning
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Charity incentives
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Self-monitoring prompts
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Coping planning
Number of subjects: 274
Study: 34378853

Group type: EXPERIMENTAL
Intervention: Tapered Implants (TIs)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Straight Implants (SIs)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tapered Implants (TIs) and Straight Implants (SIs)
Number of subjects: 48
Study: 32931412

Group type: EXPERIMENTAL
Intervention: 20 mg iron supplementation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 80 mg iron supplementation
Number of subjects: 44

Group type: COMPARATOR
Intervention: No iron supplementation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 36282854

Group type: EXPERIMENTAL
Intervention: Peer-mediated play-based intervention (10-week duration)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waitlisted control group (10-week wait)
Number of subjects: 29
Study: 35451117

Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy with infused water volume during insertion ≥ 1000 mL
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy
Number of subjects: 912
Study: 33131095

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Revaprazan 200 mg
Number of subjects: 100
Study: 35302633

Group type: EXPERIMENTAL
Intervention: Immediate card acquisition group
Number of subjects: 186

Group type: COMPARATOR
Intervention: Delayed card acquisition group
Number of subjects: 186
Study: 32052748

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-music control
Number of subjects: 126
Study: 35504234

Group type: EXPERIMENTAL
Intervention: Ketogenic medium chain triglyceride (kMCT) intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 32921535

Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine (CHG) bathing daily during the intervention period (n = 1501)
Number of subjects: 4799

Group type: COMPARATOR
Intervention: Standard care without CHG bathing during the same period (n = 3299)
Number of subjects: 4799
Study: 35835631

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition and some control of the obstruction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Treatment of the obstruction only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Untreated tumour, obstruction and starvation
Number of subjects: 20
Study: 32925679

Group type: EXPERIMENTAL
Intervention: 3D fluoroscopy-based navigation (NAV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional 2D fluoroscopy (FLUORO)
Number of subjects: 41
Study: 33413161

Group type: EXPERIMENTAL
Intervention: Low-volume month (November 2017)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: High-volume month (August 2017)
Number of subjects: 1470
Study: 32716492

Group type: EXPERIMENTAL
Intervention: Genome-wide association study
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 100000
Study: 34724587

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 15 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study: 33858205

Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS) injection: 20 mg of triamcinolone
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection: 2.5 mL of HA
Number of subjects: 186

Group type: COMPARATOR
Intervention: Normal saline (NS) injection: 2.5 mL of NS
Number of subjects: 186
Study: 34132328

Group type: EXPERIMENTAL
Intervention: Genetically predicted high serum copper levels
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: Genetically predicted high serum zinc levels
Number of subjects: 5548
Study: 34888600

Group type: EXPERIMENTAL
Intervention: EDC in water (group S)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: EDC in ethanol (group Sa)
Number of subjects: 64

Group type: COMPARATOR
Intervention: EDC in water (group S), EDC in ethanol (group E), EDC in acetone (group B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Aging groups (S0a, Sa, Ea, Ba)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 64
Study: 35240044

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg bolus)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Moderate-dose unfractionated heparin (5000 IU bolus followed by 1250 IU/h for 6 h)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin (5000 IU bolus followed by 500 IU/h for 6 h)
Number of subjects: 663

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 663

Group type: COMPARATOR
Intervention: No unfractionated heparin
Number of subjects: 663
Study: 35913722

Group type: EXPERIMENTAL
Intervention: Single-shot lumbar erector spinae plane block (ESPB) at L1
Number of subjects: 71

Group type: COMPARATOR
Intervention: No block (control)
Number of subjects: 71
Study: 33795826

Group type: EXPERIMENTAL
Intervention: HA-PCI (hippocampus-avoidance prophylactic cranial irradiation)
Number of subjects: 106

Group type: COMPARATOR
Intervention: C-PCI (conventional prophylactic cranial irradiation)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: HA-PCI
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Higher thoracic radiotherapy dose (≥ 60 Gy)
Number of subjects: 106
Study: 32819447

Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib/dexamethasone (D‐Vd)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Bortezomib/dexamethasone (Vd)
Number of subjects: 498
Study: 35219526

Group type: EXPERIMENTAL
Intervention: Mitomycin drops
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 34416369

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1224
Study: 36265571

Group type: EXPERIMENTAL
Intervention: Intact cord resuscitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clamped cord resuscitation
Number of subjects: 0
Study: 34179723

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Ketorolac and Placebo)
Number of subjects: 20
Study: 32392019

Group type: EXPERIMENTAL
Intervention: Early neuromuscular blockade in mechanically ventilated patients with moderate/severe ARDS
Number of subjects: 79
Study: 36176003

Group type: EXPERIMENTAL
Intervention: VLC-NDPP
Number of subjects: 300

Group type: COMPARATOR
Intervention: NDPP
Number of subjects: 300
Study: 33586920

Group type: EXPERIMENTAL
Intervention: Home-based multimodal symptom-management program plus usual care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 35412592

Group type: COMPARATOR
Intervention: Standard educational materials alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Standard educational materials in combination with web-based decision support tools
Number of subjects: 300
Study: 34625027

Group type: EXPERIMENTAL
Intervention: Capillary haemoglobin measurement using a haemoglobinometer on a monthly basis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current protocol at the primary care centre with venous haemoglobin measurement
Number of subjects: 0
Study: 36178742

Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 33554398

Group type: EXPERIMENTAL
Intervention: Child labor
Number of subjects: 947

Group type: COMPARATOR
Intervention: Nonworking siblings
Number of subjects: 947
Study: 32835465

Group type: EXPERIMENTAL
Intervention: Primary Care Intensive Management (PIM)
Number of subjects: 1527
Study: 35082847

Group type: EXPERIMENTAL
Intervention: NSPT with periodontal endoscopy (PE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: NSPT without periodontal endoscopy (nPE)
Number of subjects: 20
Study: 33566129

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v administered for 60 days
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo administered for 60 days
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 34672100

Group type: EXPERIMENTAL
Intervention: C + T (1 drop of cyclopentolate 1% and 1 drop of tropicamide 1%)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: C + C (2 drops of cyclopentolate 1%)
Number of subjects: 251
Study: 32877582

Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate‐taurursodiol (3 g of sodium phenylbutyrate and 1 g of taurursodiol, administered once a day for 3 weeks and then twice a day)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate‐taurursodiol
Number of subjects: 137

Group type: COMPARATOR
Intervention: Sodium phenylbutyrate‐taurursodiol and Placebo
Number of subjects: 137
Study: 35190815

Group type: EXPERIMENTAL
Intervention: 60 Gy radiation dose with concurrent chemotherapy (docetaxel 25 mg/m2; cisplatin 25 mg/m2)
Number of subjects: 319

Group type: COMPARATOR
Intervention: 50 Gy radiation dose with concurrent chemotherapy (docetaxel 25 mg/m2; cisplatin 25 mg/m2)
Number of subjects: 319
Study: 33400004

Group type: EXPERIMENTAL
Intervention: Long-term glucocorticoid treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 9
Study: 34016484

Group type: EXPERIMENTAL
Intervention: Polypill treatment
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1200
Study: 34712732

Group type: EXPERIMENTAL
Intervention: Cerebral blood oxygen saturation detection
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention specified for control group (no-POCD)
Number of subjects: 90
Study: 32814610

Group type: EXPERIMENTAL
Intervention: Pharmacist-led ATO (ATO-A)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Pharmacist-led ATO (ATO-B)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Usual Care (UC-A)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Usual Care (UC ATO-B)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Pharmacist-led ATO
Number of subjects: 538
Study: 35687008

Group type: EXPERIMENTAL
Intervention: Walnut intake (15% of daily energy from walnuts)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (usual diet, no walnuts)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 192
Study: 33155675

Group type: EXPERIMENTAL
Intervention: efavirenz-based-ART after 4 weeks of rifampicin-based anti-TB therapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: efavirenz-based-ART after 8 weeks of rifampicin-based anti-TB therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: efavirenz only
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: rifampicin only therapy for 4 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: rifampicin only therapy for 8 weeks
Number of subjects: 102
Study: 35441931

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus oral antidepressant (AD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus oral antidepressant (AD)
Number of subjects: 0
Study: 32389819

Group type: EXPERIMENTAL
Intervention: Surgical revision of midurethral sling (MUS) due to vaginal mesh extrusion
Number of subjects: 464
Study: 35175188

Group type: EXPERIMENTAL
Intervention: Pathogen reduction with riboflavin and ultraviolet light (PRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study: 36018037

Group type: EXPERIMENTAL
Intervention: Polypill (aspirin 100 mg, ramipril 2.5/5/10 mg, atorvastatin 20/40 mg)
Number of subjects: 2499

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2499
Study: 32640846

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 32044752

Group type: EXPERIMENTAL
Intervention: Constant Therapy, a remotely delivered, cloud‐based rehabilitation program for speech-language disorders, duration: first 20 weeks of program access.
Number of subjects: 2850
Study: 35074766

Group type: EXPERIMENTAL
Intervention: Brief decision aids for 3 ARIs (acute otitis media, acute sore throat, acute bronchitis) and video-delivered training
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Brief decision aids and training
Number of subjects: 122
Study: 33594755

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study: 35987683

Group type: EXPERIMENTAL
Intervention: Lavender essence inhalation
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lavender essence massage
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 121
Study: 34362787

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU per day
Number of subjects: 2166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2166
Study: 32465406

Group type: EXPERIMENTAL
Intervention: ECP treatment (16 treatments in the first three months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard triple immunosuppression: tacrolimus, mycophenolate mofetil, and steroids)
Number of subjects: 40
Study: 36369261

Group type: EXPERIMENTAL
Intervention: Female peer mentor
Number of subjects: 150

Group type: COMPARATOR
Intervention: Male peer mentor
Number of subjects: 150

Group type: COMPARATOR
Intervention: No mentor
Number of subjects: 150
Study: 35842776

Group type: EXPERIMENTAL
Intervention: Directional atherectomy system (DAS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Orbital atherectomy system (OAS)
Number of subjects: 60
Study: 34939347

Group type: EXPERIMENTAL
Intervention: Jintiange capsule for 3 months
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional postoperative treatment
Number of subjects: 106
Study: 32321301

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy individuals (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients with non‐proliferative diabetic retinopathy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients with proliferative diabetic retinopathy
Number of subjects: 90
Study: 35761367

Group type: EXPERIMENTAL
Intervention: High-volume haemodiafiltration (aiming for 21+ L of substitution fluid adjusted for body surface area)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-flux haemodialysis
Number of subjects: 0
Study: 33148945

Group type: EXPERIMENTAL
Intervention: High protein oral nutrition supplement containing HMB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 0
Study: 36482636

Group type: EXPERIMENTAL
Intervention: HIFU combined with TACE
Number of subjects: 110

Group type: COMPARATOR
Intervention: TACE (comparison group)
Number of subjects: 110
Study: 32396664

Group type: EXPERIMENTAL
Intervention: ICD-11
Number of subjects: 196

Group type: COMPARATOR
Intervention: ICD-10
Number of subjects: 196

Group type: COMPARATOR
Intervention: DSM-5
Number of subjects: 196
Study: 32579567

Group type: EXPERIMENTAL
Intervention: Alert Program® intervention (8-week program, 8 one-hour lessons)
Number of subjects: 271
Study: 36166027

Group type: EXPERIMENTAL
Intervention: High-flow oxygen
Number of subjects: 711

Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 711
Study: 32651093

Group type: EXPERIMENTAL
Intervention: One‐hour training in sleep leadership
Number of subjects: 524

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 524
Study: 35580297

Group type: EXPERIMENTAL
Intervention: Aumolertinib (110 mg once daily)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Gefitinib (250 mg once daily)
Number of subjects: 429
Study: 33743621

Group type: EXPERIMENTAL
Intervention: WHO standard of care (SOC) plus rapid TB detection using Xpert MTB/RIF Ultra on nasopharyngeal aspirates and stool samples.
Number of subjects: 3780

Group type: COMPARATOR
Intervention: WHO standard of care (SOC) for severe pneumonia.
Number of subjects: 3780
Study: 36088298

Group type: EXPERIMENTAL
Intervention: Morning surgery group (group A, 8:00–12:00)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Afternoon surgery group (group P, 14:00–18:00)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups (morning and afternoon surgeries)
Number of subjects: 59
Study: 34967165

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol + Canephron N (2 tablets t.i.d. for 2 weeks)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Fosfomycin trometamol (3 g, single dose)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol + Canephron N
Number of subjects: 112
Study: 34114918

Group type: EXPERIMENTAL
Intervention: Longvida® optimized curcumin (1.0 g/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 36
Study: 32966051

Group type: EXPERIMENTAL
Intervention: Shortest-distance routes
Number of subjects: 14091

Group type: EXPERIMENTAL
Intervention: Alternative lowest-dose route
Number of subjects: 14091

Group type: COMPARATOR
Intervention: Simulated addresses
Number of subjects: 14091

Group type: EXPERIMENTAL
Intervention: Exposure inequality analysis
Number of subjects: 14091
Study: 35908118

Group type: EXPERIMENTAL
Intervention: n-3 long chain polyunsaturated fatty acids (LCPUFA)
Number of subjects: 300
Study: 34144486

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for a median of 28 days
Number of subjects: 108
Study: 35664504

Group type: EXPERIMENTAL
Intervention: Overground wearable-exoskeleton training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Functional kinematic therapy
Number of subjects: 50
Study: 32029450

Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol
Number of subjects: 407

Group type: COMPARATOR
Intervention: Maintenance budesonide
Number of subjects: 407
Study: 36829111

Group type: EXPERIMENTAL
Intervention: 10-µg FAKHRAVAC vaccine
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 33689709

Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 12515
Study: 32857128

Group type: EXPERIMENTAL
Intervention: HMB+D + no exercise
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control + no exercise
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: HMB+D + exercise
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control + exercise
Number of subjects: 117
Study: 36116775

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of dexamethasone per day for 1 to 2 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of dexamethasone per day for 1 to 2 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of dexamethasone
Number of subjects: 0
Study: 32785666

Group type: EXPERIMENTAL
Intervention: VEN + R (arm A)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: VEN + BR (arm B)
Number of subjects: 163

Group type: COMPARATOR
Intervention: BR (arm C)
Number of subjects: 163
Study: 34138817

Group type: EXPERIMENTAL
Intervention: Endurance training (END)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 78
Study: 32801090

Group type: EXPERIMENTAL
Intervention: TMS to the left anterior STG (laSTG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TMS to the left posterior STG (lpSTG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TMS to the right anterior STG (raSTG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control region (posterior occipital lobe)
Number of subjects: 20
Study: 35952357

Group type: EXPERIMENTAL
Intervention: ART during breastfeeding cessation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Higher TFV levels
Number of subjects: 55
Study: 33740407

Group type: EXPERIMENTAL
Intervention: Resilience-based psychosocial HIV prevention intervention (group and individual counselling, HIV and STI voluntary counselling and testing)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Standard-of-care control (voluntary counselling and testing alone)
Number of subjects: 608
Study: 34983010

Group type: EXPERIMENTAL
Intervention: Oxytocin 20 IU
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oxytocin 40 IU
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ambiguous threat (PTSD-AUD only)
Number of subjects: 47
Study: 34161523

Group type: EXPERIMENTAL
Intervention: Unstable shoes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional shoes
Number of subjects: 0
Study: 35630046

Group type: EXPERIMENTAL
Intervention: Visual cue deprivation balance training with head control feedback
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study: 33980512

Group type: EXPERIMENTAL
Intervention: PROSPER exercise intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 20
Study: 32584290

Group type: EXPERIMENTAL
Intervention: Face‐to‐face health counseling on SHS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Written educational pamphlet only (Control)
Number of subjects: 100
Study: 36435397

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS + agomelatine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham rTMS + agomelatine
Number of subjects: 100
Study: 34015036

Group type: EXPERIMENTAL
Intervention: Salbutamol (2 puffs of 200 μg) 30 min before anesthesia induction and 30 min before surgery completion
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 63